Antipsychotics for patients with pain
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Going back to basics prior to mentioning the use of antipsychotics in patients with pain, the International Association for the Study of Pain (IASP) definition of pain can be summarized as an unpleasant experience, composed of sensory experience caused by actual tissue damage and/or emotional experience caused by potential tissue damage. Less used than antidepressants, antipsychotics have also been used for treating this unpleasant experience as adjuvant analgesics without sufficient evidence from research. Because recently developed atypical antipsychotics reduce the adverse reactions of extrapyramidal symptoms, such as acute dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia caused by typical antipsychotics, they are expected to be used more frequently in various painful conditions, while increasing the risk of metabolic syndromes (weight gain, diabetes, and dyslipidemia). Various antipsychotics have different neurotransmitter receptor affinities for dopamine (D), 5-hydroxytryptamine (5-HT), adrenergic (), histamine (H), and muscarinic (M) receptors. Atypical antipsychotics antagonize transient, weak D2 receptor bindings with strong binding to the 5-HT2A receptor, while typical antipsychotics block long-lasting, tight D2 receptor binding. On the contrary, antidepressants in the field of pain management also block the reuptake of similar receptors, mainly on the 5-HT and, next, on the norepinephrine, but rarely on the D receptors. Antipsychotics have been used for treating positive symptoms, such as delusion, hallucination, disorganized thought and behavior, perception disturbance, and inappropriate emotion, rather than the negative, cognitive, and affective symptoms of psychosis. Therefore, an antipsychotic may be prescribed in pain patients with positive symptoms of psychosis during or after controlling all sensory components.
Abstract
Going back to basics prior to mentioning the use of antipsychotics in patients with pain, the International Association for the Study of Pain (IASP) definition of pain can be summarized as an unpleasant experience, composed of sensory experience caused by actual tissue damage and/or emotional experience caused by potential tissue damage. Less used than antidepressants, antipsychotics have also been used for treating this unpleasant experience as adjuvant analgesics without sufficient evidence from research. Because recently developed atypical antipsychotics reduce the adverse reactions of extrapyramidal symptoms, such as acute dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia caused by typical antipsychotics, they are expected to be used more frequently in various painful conditions, while increasing the risk of metabolic syndromes (weight gain, diabetes, and dyslipidemia). Various antipsychotics have different neurotransmitter receptor affinities for dopamine (D), 5-hydroxytryptamine (5-HT), adrenergic (), histamine (H), and muscarinic (M) receptors. Atypical antipsychotics antagonize transient, weak D2 receptor bindings with strong binding to the 5-HT2A receptor, while typical antipsychotics block long-lasting, tight D2 receptor binding. On the contrary, antidepressants in the field of pain management also block the reuptake of similar receptors, mainly on the 5-HT and, next, on the norepinephrine, but rarely on the D receptors. Antipsychotics have been used for treating positive symptoms, such as delusion, hallucination, disorganized thought and behavior, perception disturbance, and inappropriate emotion, rather than the negative, cognitive, and affective symptoms of psychosis. Therefore, an antipsychotic may be prescribed in pain patients with positive symptoms of psychosis during or after controlling all sensory components.
참고문헌 (38)
- "Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy", Pain, 6, pp.249~ (1979)
- Stroup TS, "Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations", Nat Rev Drug Discov, 5, pp.133~146 (2006)
- Targum SD, "Treating psychotic symptoms in elderly patients", Prim Care Companion J Clin Psychiatry, 3, pp.156~163 (2001)
- Leo RJ, "Atypical antipsychotic use in the treatment of psychosis in primary care", Prim Care Companion J Clin Psychiatry, 2, pp.194~204 (2000)
- Seidel S, "Antipsychotics for acute and chronic pain in adults", Cochrane Database Syst Rev, pp.CD004844~ (2008)
- Seidel S, "Antipsychotics for acute and chronic pain in adults", J Pain Symptom Manage, 39, pp.768~778 (2010)
- Ramachandraiah CT, "The story of antipsychotics : past and present", Indian J Psychiatry, 51, pp.324~326 (2009)
- Worrel JA, "Atypical antipsychotic agents : a critical review", Am J Health Syst Pharm, 57, pp.238~255 (2000)
- Gottfries CG, "Flupenthixol decanoate--in treatment of out-patients", Acta Psychiatr Scand Suppl, 255, pp.15~24 (1974)
- Kapur S, "Half a century of antipsychotics and still a central role for dopamine D2 receptors", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.1081~1090 (2003)
- Howes OD, "The dopamine hypothesis of schizophrenia : version III--the final common pathway", Schizophr Bull, 35, pp.549~562 (2009)
- Yang AC, "New targets for schizophrenia treatment beyond the dopamine hypothesis", Int J Mol Sci, 18, pp.1689~ (2017)
- Inada T, "Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to i ts usage" (1996), Seiwa Shoten Publishers
- Knol W, "Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research", J Clin Psychopharmacol, 30, pp.57~63 (2010)
- Chouinard G, "Manual for the Extrapyramidal Symptom Rating Scale(ESRS)", Schizophr Res, 76, pp.247~265 (2005)
- Holloman LC, "Management of acute extrapyramidal effects induced by antipsychotic drugs", Am J Health Syst Pharm, 54, pp.2461~2477 (1997)
- Albanese A, "Phenomenology and classification of dystonia : a consensus update", Mov Disord, 28, pp.863~873 (2013)
- Skogseid IM, "Dystonia--new advances in classification, genetics, pathophysiology and treatment", Acta Neurol Scand, 129, pp.13~19 (2014)
- Kurlan R, "P seudoparkinsonism: a review of a common nonparkinsonian hypokinetic movement disorder", Adv Parkinson Dis, 2, pp.108~112 (2013)
- Glazer WM, "Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications", J Clin Psychiatry, 54, pp.133~139 (1993)
- Munetz MR, "Screening for tardive dyskinesia", J Clin Psychiatry, 47, pp.75~77 (1986)
- Uhlyar S, "Valbenazine(Ingrezza) : the first FDAapproved treatment for tardive dyskinesia", P T, 43, pp.328~331 (2018)
- Markowitz JD, "Delirium and antipsychotics:a systematic review of epidemiology and somatic treatment options", Psychiatry (Edgmont), 5, pp.29~36 (2008)
- Seeman P, "Atypical antipsychotics : mechanism of action", Can J Psychiatry, 47, pp.27~38 (2002)
- Glazer WM, "Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality", J Clin Psychiatry, 61, pp.16~21 (2000)
- Miller DD, "Atypical antipsychotics : sleep, sedation, and efficacy", Prim Care Companion J Clin Psychiatry, 6, pp.3~7 (2004)
- Brixner DI, "Naturalistic impact of second-generation antipsychotics on weight gain", Ann Pharmacother, 40, pp.626~632 (2006)
- Gentile S., "Contributing factors to weight gain during longterm treatment with second-generation antipsychotics. A systematic appraisal and clinical implications", Obes Rev, 10, pp.527~542 (2009)
- Roerig JL, "Atypical antipsychoticinduced weight gain : insights into mechanisms of action", CNS Drugs, 25, pp.1035~1059 (2011)
- Taylor DM, "Atypical antipsychotics and weight gain--a systematic review", Acta Psychiatr Scand, 101, pp.416~432 (2000)
- Cohen D., "Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature", Pharmacopsychiatry, 37, pp.1~11 (2004)
- Schwenkreis P, "Atypical antipsychotics and diabetes mellitus", World J Biol Psychiatry, 5, pp.73~82 (2004)
- Haupt DW, "Hyperglycemia and antipsychotic medications", J Clin Psychiatry, 62, pp.15~26 (2001)
- Leucht S, "Dose equivalents for second-generation antipsychotics : the minimum effective dose method", Schizophr Bull, 40, pp.314~326 (2014)
- Leucht S, "Dose equivalents for second-generation antipsychotic drugs : the classical mean dose method", Schizophr Bull, 41, pp.1397~1402 (2015)
- Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
- Khouzam HR, "Psychopharmacology of chronic pain : a focus on antidepressants and atypical antipsychotics", Postgrad Med, 128, pp.323~330 (2016)
- Gardner DM, "Modern antipsychotic drugs : a critical overview", CMAJ, 172, pp.1703~1711 (2005)